Ann Tsukamoto
Ann S. Tsukamoto Weissman[1] (born July 6, 1952) is an Asian American stem cell researcher and inventor.[2][3] In 1991, she co-patented a process that allowed the human stem cell to be isolated and demonstrated their potential in treating patients with metastatic breast cancer.[1] Tsukamoto’s research and contributions in the medical field have led to groundbreaking advancements in stem cell research, especially in understanding the blood systems of cancer patients.[4] Her work has shown potential treatments for cancers and neurological disorders, for which there were previously thought to be none.[1][4][5] CareerAnn Tsukamoto was born in California on July 6, 1952.[6] She completed her bachelor's degree at the University of California San Diego and her Ph.D in immunology and microbiology at the University of California Los Angeles.[6][7][8] Ann did most of her postdoctoral work at the University of California, San Francisco.[7] Here, she worked on the wnt-1 gene and developed a transgenic model for breast cancer. Wnt-1 was later discovered to be a key player in the stem cell self-renewal pathway.[8] She joined the biotech company SyStemix from 1989 to 1997,[9] where she co-discovered the human hematopoietic stem cell (hHSC) and played a leading role in the launch of the clinical research program for this cell. The purified hHSC was shown to be cancer-free when isolated from the cancer-contaminated hematopoietic mobilized blood of patients with disseminated cancer, and it successfully regenerated the patients' blood-forming system after myeloablative chemotherapy.[8] Ann joined StemCells Inc. in 1998, where she has held several leadership roles overseeing the isolation and application of human neural and liver stem cells for various diseases.[9] She led the scientific team that discovered the human central nervous system stem cell and identified a second candidate stem cell for the liver. Under her guidance, the human neural stem cell transitioned into early clinical development for all three components of the central nervous system: the brain, spinal cord, and eye. The biological potential and activity of these cells were demonstrated in some patients, mirroring the results observed in preclinical rodent studies.[8] As of 2017, Tsukamoto is an inventor on seven issued U.S. patents, six of which are related to the human hematopoietic stem cell.[8] By 2021, she had reached a total of 13 patents.[7] References
|